SCAI-001 not checked

SCAI Therapeutics · Cyclosporine 0.01% · Cyclosporine 0.02%

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Dry Eye Syndromes
Main trialPhase 2
“This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.”In the company’s words, NCT05733624 on ClinicalTrials.gov
Other names
Cyclosporine 0.01% · Cyclosporine 0.02%
Copy of
Restasis (Allergan)Tested side by side with the original in NCT05733624

Other drugs for Dry Eye Syndromes

All 44 drugs for Dry Eye Syndromes

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Completed 23 Aug 2023 Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow SCAI-001

Following is part of Solo: you see every change to SCAI-001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in